Semaglutide Brand Names: Ozempic, Wegovy, and Rybelsus Explained

Semaglutide is the active molecule. Ozempic, Wegovy, and Rybelsus are the brand names Novo Nordisk has built around it for different indications and delivery methods. Understanding the relationship between the three helps explain why your doctor might prescribe one instead of another — and why your insurance may cover one but not the rest.

Ozempic — injectable, diabetes

Ozempic is a once-weekly subcutaneous injection approved for the treatment of type 2 diabetes in adults. It comes in pre-filled pens at doses of 0.5 mg, 1 mg, and 2 mg. Ozempic also carries an FDA-approved indication to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease — a clinically significant approval that goes beyond blood sugar control.

Weight loss is a well-documented effect of Ozempic, but it is not the approved indication. Prescribing it specifically for weight management is off-label use, which insurers typically do not cover.

Wegovy — injectable, weight management

Wegovy is the same semaglutide molecule, also injected once weekly, but approved specifically for chronic weight management. Its maximum dose — 2.4 mg weekly — is higher than Ozempic's 2 mg ceiling, and the dosing protocol is structured differently: it takes 16 weeks to reach the maintenance dose through a 5-step titration.

Wegovy is approved for adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It is also approved for adolescents aged 12 and older with obesity — the first GLP-1 with that specific paediatric approval.

Rybelsus — oral, diabetes

Rybelsus is the oral formulation of semaglutide — a tablet taken once daily, on an empty stomach, with a small amount of water. It is approved for type 2 diabetes only, not for weight management. Available doses are 3 mg, 7 mg, and 14 mg.

The bioavailability of oral semaglutide is significantly lower than the injectable form — the drug must survive the digestive environment, which requires co-formulation with a special absorption enhancer. Head-to-head data suggests injectable semaglutide produces modestly greater HbA1c reductions and weight loss than the oral version at comparable doses, though Rybelsus remains a meaningful option for patients who strongly prefer to avoid injections.

Why three names for one molecule?

Novo Nordisk created separate brand identities because each product went through a distinct FDA approval process for a distinct indication. The approval pathway determines the label, the label determines the indication, and the indication determines insurance coverage. From a regulatory and payer standpoint, Ozempic, Wegovy, and Rybelsus are different products — even though they share an active ingredient.

Which one might you be prescribed?

• Type 2 diabetes, injectable preferred → Ozempic
• Obesity or overweight with a health condition, injectable → Wegovy
• Type 2 diabetes, strong preference to avoid injections → Rybelsus
• Paying cash and want the active ingredient at lower cost → Compounded semaglutide through a telehealth provider

This is educational content. The right semaglutide product for your situation depends on your diagnosis, insurance, and preferences — a licensed clinician should guide that decision.